Background Atypical hemolytic uremic syndrome (aHUS) is a form of thrombotic microangiopathy (TMA) caused by dysregulation of the complement system. Outcomes of kidney transplantation are poor owing to aHUS recurrence and loss of graft. Patients carrying CFH mutations or CFH/CFHR1 hybrid genes present a very high risk of recurrence despite preventive plasmapheresis. Evaluation of recent data suggests that prophylactic eculizumab pretransplant might be the preferred therapy if available. Case-diagnosis/treatment We report 3-year follow-up data in a 9-year-old boy with aHUS and successful renal transplant treated with prophylactic eculizumab without recurrence. He presented with aHUS at age 3, irreversible renal failure and uncontrolled severe hypertension with concentric left ventricular hypertrophy, recurrent acute pulmonary edema, and congestive heart failure despite five hypotensive agents and bilateral nephrectomy. Complement analysis demonstrated the presence of a CFH/CFHR1 hybrid gene inherited from his mother and a SNP risk CFH haplotype inherited from his father. Kidney transplant was performed with prophylactic eculizumab and subsequent fortnightly administration. Three years posttransplant, graft function remains stable (serum creatinine 0.9 mg/dl), hypertension is controlled, no left ventricular hypertrophy, no opportunistic infections, and negative clinical chemistry parameters for hemolysis. Conclusion Eculizumab is a safe and effective therapy for preventing TMA recurrence and provides long-term graft function in aHUS with the CFH/CFHR1 hybrid gene.
Introduction
Atypical hemolytic uremic syndrome (aHUS) is a form of thrombotic microangiopathy (TMA) caused by dysregulation of the complement system. The prognosis is poor and over half of patients progress to end-stage renal disease or die. Conventional renal transplantation is not a safe treatment option owing to the high risk of recurrence and loss of the graft [1] . Patients on dialysis have poorer chances of survival and present cardiovascular risk secondary to hypertension. The efficacy of plasmapheresis is transient and the morbidity/mortality rates for combined liver-kidney transplant are high.
Eculizumab is a humanized anti-C5 monoclonal antibody that blocks activation of the terminal complement cascade. It has recently been approved for the treatment of aHUS and shown to be effective both in native and non-native kidneys. Nine patients had received prophylactic eculizumab to prevent post-transplant aHUS recurrence [2] .
We report 3-year follow-up data in a boy with aHUS and renal transplant treated with prophylactic eculizumab without recurrence.
Case report
Our 9-year-old patient presented at age 3 with oliguric renal disease, microangiopathic hemolytic anemia with schistocytes and thrombocytopenia. He had no diarrhea or neurological symptoms, and his stool cultures were negative. Hypertension, hematuria, and nephrotic syndrome were present from onset (serum creatinine 2.57 mg/dl, creatinine clearance 20 ml/min/ 1.73 m 2 , hemoglobin 8.8 g/dl, platelets 55,000/mm 3 , LDH 2445 UI, undetectable haptoglobin, nephrotic proteinuria, albumin 2.7 g/dl). Hemodialysis was started on day 9 with serum creatinine of 5.8 mg/dl and thrombocytopenia (31,000/mm 3 ). Anemia (Hb 5.8 g/dl) persisted, despite five transfusions of cell concentrate in the first month.
Continuing on dialysis for 4 years the patient had two further hemolytic crises requiring transfusion and also experienced persistent headaches, abdominal pain, paresthesia, and general malaise. The clinical course was dominated by uncontrolled hypertension with concentric left ventricular hypertrophy despite daily hemodialysis and 5 hypotensive agents. He suffered three hypertensive crises with acute pulmonary edema and congestive heart failure. In view of life-threatening hypertension, bilateral nephrectomy was decided 3 months after initial onset. Renal pathology showed cortical glomerular cystic transformation and severe arteriosclerosis. However, severe hypertension continued to be poorly controlled. He had two further hypertensive crises, the second being 2.5 years after onset and involving hypertonic seizure and cardiorespiratory arrest.
Complement assessment
Complement analysis in the patient and his relatives illustrated normal levels of C3, C4, FI, FB, and FH. Assays to identify C3Nef or anti-FH autoantibodies were negative. Levels of membrane cofactor protein (MCP) on the surface of peripheral blood lymphocytes were also normal. Functional analysis of FH, using a sheep red cell hemolytic assay [3] , demonstrated an abnormal FH activity in the patient and in three of his relatives (Table 1) , which suggested that the patient and his relatives carry a functional alteration in the C-terminal region of FH. Importantly, this type of functional alteration in FH is prototypical of aHUS [4] .
Sequencing analyses identified that the patient and the relatives with functional alteration in FH carry two genetic variations in the CFH gene (c.2669G>T, p.Ser890Ile and c.3019G >T, p.Val1007Leu) in heterozygosity ( Supplementary Fig. 1 ). In addition, multiplex ligation-dependent probe amplification (MLPA) identified in these individuals a genetic rearrangement in the CFH-CFHR region resulting in a CFH/CFHR1 hybrid gene similar to that previously found in other aHUS patients ( Table 1 ; Supplementary Fig. 1 ) [5] . The product of this hybrid gene is a mutant FH protein in which the C-terminal region is substituted for the C-terminal region of FHR1, introducing two amino acid changes, Ser1191Leu and Val1197Ala. Interestingly, the Ser890Ile and Val1007Leu genetic variations and the hybrid gene segregate together in the same CFH allele. In summary, the FH protein encoded by this CFH/CFHR1 gene presents four amino acid differences compared with the FH reference protein ( Supplementary Fig. 1 ). No mutations were found in CFI, MCP, C3, CFB, and THBD.
Kidney transplantation under eculizumab
The patient's condition on hemodialysis continued to be lifethreatening. Published results showed effective inhibition of complement-mediated TMA by eculizumab in aHUS [6, 7] . In 2010, 4 years after onset, deceased donor kidney transplantation was proposed with pre-emptive eculizumab treatment. Informed consent was obtained from the family for treatment under terms of compassionate use.
Prior to transplantation the patient was appropriately immunized against Haemophilus influenzae, Pneumococcus, viral hepatitis B, varicella, and tetravalent meningococcal vaccine. Anti-HLA antibodies were negative. A kidney transplant was scheduled with induction using basiliximab, prednisone, mycophenolate mofetil, and tacrolimus, plus prophylactic eculizumab. The regimen consisted of administration of the first dose of eculizumab 600 mg 6 h pre-transplant, then within 24 h, then four weekly doses and subsequently, doses of 600 mg in fortnightly cycles.
Kidney transplantation was performed from a deceased donor with three compatibilities. There was immediate diuresis on unclamping. Serum creatinine decreased from 9 to 0.7 mg/ dl over the initial few weeks post-transplant. There were no side effects after administration of eculizumab. He was started on tacrolimus on day +2, and the steady decrease in creatinine continued. He received prophylaxis with valganciclovir, cotrimoxazole, and phenoxybenzylpenicillin (ongoing).
In the first week post-transplant, the patient developed a surgical complication consisting of punctiform intestinal perforation without TMA signs resolved by simple suturing. One month after surgery, a bladder fistula was resolved with a double J stent. He developed Klebsiella pyelonephritis related to the catheter, which was resolved without complications. There were no clinical or laboratory signs showing complement activity during the episodes of infection, thus requiring no modification of the eculizumab treatment regimen. Three years post-transplant, graft function continues to be stable, serum creatinine 0.9 mg/dl, no proteinuria, Hb 11.9 g/dl, normal platelets, hypertension controlled with calcium channel blocker and beta blocker without ventricular hypertrophy, no cytotoxic antibodies, negative BK viruria, no cytomegalovirus (CMV) infection and negative clinical chemistry parameters for hemolysis. He has remained free of any further evidence of TMA with fortnightly administration of eculizumab as an outpatient, with the current dose of 900 mg adjusted to body weight. His growth is normal, as are his activities and performance at school, with full social and familial integration.
Discussion
Our experience supports the utility and safety of eculizumab for the prevention of aHUS recurrence post-transplant in patients carrying a CFH/CFHR1 hybrid gene. There are reports of 9 patients with aHUS who have been treated with eculizumab prior to renal transplant in the literature, 4 with prophylactic plasma therapy preceded by eculizumab and 5 with eculizumab alone [2] . Two patients had a CFH/CFHR1 hybrid gene [8, 9] . Our patient's outcome is favorable and renal function normal 36 months after kidney transplantation without recurrence. He remains free of any further clinical TMA manifestations taking eculizumab alone.
The genetic analysis allows us to conclude that the CFH/ CFHR1 hybrid gene is the underlying genetic defect responsible for aHUS in our patient. The FH/FHR1 hybrid protein encoded by this gene is unable to provide appropriate regulation of the C3 convertase, exposing platelets and endothelium to the uncontrolled activation of the complement pathway that characterizes aHUS. The CFH/CFHR1 hybrid gene in our patient carries two additional nucleotide changes that are irrelevant. In fact, in a separate study, we have recently shown that Ser890Ile and Val1007Leu genetic variations are polymorphisms with no functional consequences [10] . The CFH/ CFHR1 hybrid gene was inherited from the mother and likely originated earlier in that lineage, since is it also found in one of the patient's aunts. The CFH/CFHR1 hybrid gene is necessary, but not sufficient to develop aHUS, as is clearly illustrated by the fact that three other relatives carrying it have not developed aHUS. Previously, it has been shown that the incomplete penetrance of the disease in carriers of mutations associated with aHUS can be explained by the concurrence of additional genetic or environmental factors [11, 12] . Analysis of the levels of expression of the normal and mutant CFH alleles in the carriers of CFH/CFHR1 hybrid gene in the pedigree of the patient (Supplementary Fig. 1 ) suggests that different levels of FH produced from the normal CFH allele in these individuals is a plausible explanation for the incomplete penetrance of the disease in this pedigree. In addition, our patient carries the CFH SNP haplotype associated with increased risk of aHUS, inherited from his father ( Table 1) .
The prognosis for aHUS in patients with complement abnormalities is very poor as a result of the progression to renal failure, TMA in other organs, ineffectiveness of conventional treatments, and the high risk of post-transplant recurrence with loss of graft. TMA occurs systemically in up to 48 % of patients and in 38 % of cases is associated with macro-and microvascular thrombosis, hence the survival rate of <40 % in dialysis patients. The risk of recurrence is higher for carriers of mutations in CFH, CFB, C3, and the CFH/CFHR1 hybrid gene. The therapeutic response to plasma therapy in both native kidney and renal graft is poor and transient.
Identification of the genetic defect in our patient and the highly associated risk of morbidity/mortality ruled out conventional renal transplant. The discouraging results reported with combined liver-kidney transplantation also led us to rule out that option, owing to the complexity of the procedure with the particularly high risk of uncontrolled ischemia/reperfusion-induced complement activation, despite extensive plasmatherapy, early graft failure, and serious infection.
The efficacy of eculizumab in blocking complement activity and preserving renal function in native-kidney aHUS presented a promising therapeutic option for our patient. Treatment was indicated under the terms of compassionate use; it was in fact subsequently approved for the treatment of aHUS by the FDA in September 2011 and in Europe in November 2011. Our treatment strategy consisted of administering a pre-transplant dose immediately before surgery and 24 h after to block the uncontrolled complement activation induced by the ischemia/ reperfusion. Subsequently, it was given weekly for 4 weeks and then at 10-to 14-day intervals. The patient has remained free of clinical manifestations of TMA on this therapy.
A recently-published study reported on 9 patients with aHUS treated pre-transplant with eculizumab, 4 of them on combined treatment with plasmapheresis, and 13 cases treated for recurrent HUS post-transplant [2] . The same strategy as described in our case was used in 5 of the 9 patients treated pre-transplant. All the patients who received prophylactic treatment remain free of recurrence and the patients treated for relapses achieved remission after a median period of 8 months. At over 3 years since transplant, this patient has the longest follow-up period to be published so far.
In aHUS patients, drug administration intervals longer than 2 weeks have been associated with early relapse and loss of graft refractory to eculizumab and plasmapheresis [1] . Eculizumab blocks the last phase in the pathogenesis of aHUS: the formation of the membrane attack complex. Therefore, in high-risk mutations the treatment is lifelong since the optimal duration of eculizumab treatment has not yet been properly addressed [2, 13] . Close monitoring is vital for early detection of insufficient complement inhibition since in some patients the recommended empirical doses may be too low, particularly in the course of respiratory infections, CMV, Epstein Barr virus (EBV), and polyomavirus. This highlights the importance of monitoring for viral replication in these patients. The classic markers of extravascular hemolysis do not provide an early warning of recurrence. Early markers must therefore be developed that are accessible in clinical practice, such as a C5-dependent functional test or the terminal complex test, for patient follow-up. Undetectable total hemolytic complement (CH50) activity suggests blockage of circulating C5. However, the detection of TMA in a renal biopsy in the absence of CH50 in two published cases with post-transplant aHUS suggests that tests are not yet sensitive enough for routine monitoring.
In our experience, eculizumab is well tolerated and has kept the patient free of renal and systemic TMA over 3 years of continuous treatment, with no infectious complications on prophylaxis with oral penicillin. Graft function remains stable, BP is well controlled and he has not developed opportunistic infections. He continues on fortnightly eculizumab therapy administered as an outpatient, allowing him to attend school and enjoy full social and familial relationships.
This case adds to the evidence of the efficacy of eculizumab prior to kidney transplantation in preventing progression of aHUS post-transplant and in the long term without the need for plasmapheresis. The development of early markers sensitive to disease activity would make it possible in the future to individualize the dose and frequency of administration, minimizing the risk of relapse.
